Oriol Mirallas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oriol Mirallas has a total of 523 co-authors. Here are the top co-authors by number of shared publications:
- David S. Hong
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
28 shared publications - Amadeo B. Biter
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3
27 shared publications - Amber Johnson
The University of Texas MD Anderson Cancer Center 2 Molecular Diagnostics Laboratory, Division of Pathology and Laboratory Medicine Houston, Texas
27 shared publications - Amir Anthony Jazaeri
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications - Barrett C. Lawson
Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
27 shared publications - David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
27 shared publications
Latest Publications
- 15 November 2026
- Published by Elsevier in Pharmacology & Therapeutics
- p. 109146
Emerging strategies targeting the Hippo–YAP/TEAD pathway and the translational relevance in solid tumors
- 15 November 2026
- Published by Elsevier in Pharmacology & Therapeutics
- p. 109146
Emerging strategies targeting the Hippo–YAP/TEAD pathway and the translational relevance in solid tumors
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4234-4245
“SMAC”-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?
Xevinapant, an antagonist of inhibitor of apoptosis proteins (IAP) from the second mitochondrial activator of caspases (SMAC)–mimetic drug class, was developed to restore apoptosis in cancer cells. Preclinical studies demonstrated on-target IAP degradation, caspase activation, and proinflammatory apoptosis via TNFα upregulation. Monotherapy activity was modest in both preclinical and phase I studies, pointing to a primarily synergistic role as a (chemo)radiosensitizer, with the strongest antitumor signals observed in head and neck squamous cell carcinoma (HNSCC). In the Debio1143-201 phase II trial in locally advanced HNSCC, adding xevinapant to chemoradiation dramatically improved locoregional control and suggested favorable long-term survival, raising hopes for the first practice-changing advance in concomitant chemoradiotherapy in two decades. Unexpectedly, the TrilynX phase III trial was definitively negative, showing detrimental effects on survival and greater toxicity, which halted the development of SMAC mimetics as anticancer drugs. High intratumoral drug exposure was confirmed, but supporting pharmacodynamic data were largely derived from indirect proapoptotic signals in peripheral blood biomarkers. In this study, we review xevinapant’s trajectory, highlighting both the promise and risks of apoptosis-directed therapies, and extract key lessons for future oncology drug development by examining existing preclinical evidence, pharmacodynamic biomarkers, trial design and interpretation, and challenges associated with dosing agents that have a narrow therapeutic index.
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4234-4245
“SMAC”-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?
Xevinapant, an antagonist of inhibitor of apoptosis proteins (IAP) from the second mitochondrial activator of caspases (SMAC)–mimetic drug class, was developed to restore apoptosis in cancer cells. Preclinical studies demonstrated on-target IAP degradation, caspase activation, and proinflammatory apoptosis via TNFα upregulation. Monotherapy activity was modest in both preclinical and phase I studies, pointing to a primarily synergistic role as a (chemo)radiosensitizer, with the strongest antitumor signals observed in head and neck squamous cell carcinoma (HNSCC). In the Debio1143-201 phase II trial in locally advanced HNSCC, adding xevinapant to chemoradiation dramatically improved locoregional control and suggested favorable long-term survival, raising hopes for the first practice-changing advance in concomitant chemoradiotherapy in two decades. Unexpectedly, the TrilynX phase III trial was definitively negative, showing detrimental effects on survival and greater toxicity, which halted the development of SMAC mimetics as anticancer drugs. High intratumoral drug exposure was confirmed, but supporting pharmacodynamic data were largely derived from indirect proapoptotic signals in peripheral blood biomarkers. In this study, we review xevinapant’s trajectory, highlighting both the promise and risks of apoptosis-directed therapies, and extract key lessons for future oncology drug development by examining existing preclinical evidence, pharmacodynamic biomarkers, trial design and interpretation, and challenges associated with dosing agents that have a narrow therapeutic index.
- Open Access
- 30 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1049-1065
Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls
- 30 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1049-1065
Open AccessTargeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls
- Open Access
- 12 April 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116745
Evolving landscape of targeted therapies in early phase clinical trials
- 12 April 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116745
Open AccessEvolving landscape of targeted therapies in early phase clinical trials
- Open Access
- 11 February 2026
- Published by Elsevier in SSRN Electronic Journal
Structural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020
Background: National trends in sepsis-associated cancer mortality in the USA remain incompletely characterised, particularly regarding long-term structural shifts and their variation across oncologic subpopulations.Methods: We conducted a population-based time-series analysis using the CDC WONDER Multiple Cause of Death database (1999–2020). Cases were defined by an underlying cause of death of malignant neoplasm (ICD-10 codes C00–C97) and a contributing cause of sepsis (A40–A41). We calculated age-standardised mortality rates (ASMR) indexed to the 2000 US Standard Population. Temporal dynamics were assessed using segmented Poisson regression to estimate annual percent changes (APC) and identify structural breakpoints. Furthermore, we employed counterfactual modelling to quantify excess mortality by projecting pre-2010 trends forward, and performed stratified analyses by cancer type (solid vs haematological), sex, and geography.Findings: Of 14 713 914 cancer deaths, 455 369 (3·10%) involved sepsis. Crude mortality increased from 6·26 to 7·94 per 100 000. Segmented regression identified a structural acceleration in the early 2010s, with APCs increasing from 0·47% (95% CI 0·36–0·57) to 2·84% (2·54–3·13). This inflection corresponded to an estimated 31 896 excess deaths compared with historical trends. Crucially, trends diverged by cancer type: mortality declined for haematological malignancies (APC −1·97%; 95% CI −2·21 to −1·73) but surged for solid tumours (APC 2·25%; 95% CI 2·10–2·39). Population ageing accounted for 77·1% of the post-inflection increase; COVID-19 contributions were transient.Interpretation: A structural acceleration in sepsis-associated cancer mortality began in the early 2010s, driven largely by solid tumours and exceeding demographic expectations. This identifies sepsis as a critical, structural determinant of cancer outcomes, necessitating prioritisation within oncologic survivorship guidelines and health system infrastructure.
- 11 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessStructural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020
Background: National trends in sepsis-associated cancer mortality in the USA remain incompletely characterised, particularly regarding long-term structural shifts and their variation across oncologic subpopulations.Methods: We conducted a population-based time-series analysis using the CDC WONDER Multiple Cause of Death database (1999–2020). Cases were defined by an underlying cause of death of malignant neoplasm (ICD-10 codes C00–C97) and a contributing cause of sepsis (A40–A41). We calculated age-standardised mortality rates (ASMR) indexed to the 2000 US Standard Population. Temporal dynamics were assessed using segmented Poisson regression to estimate annual percent changes (APC) and identify structural breakpoints. Furthermore, we employed counterfactual modelling to quantify excess mortality by projecting pre-2010 trends forward, and performed stratified analyses by cancer type (solid vs haematological), sex, and geography.Findings: Of 14 713 914 cancer deaths, 455 369 (3·10%) involved sepsis. Crude mortality increased from 6·26 to 7·94 per 100 000. Segmented regression identified a structural acceleration in the early 2010s, with APCs increasing from 0·47% (95% CI 0·36–0·57) to 2·84% (2·54–3·13). This inflection corresponded to an estimated 31 896 excess deaths compared with historical trends. Crucially, trends diverged by cancer type: mortality declined for haematological malignancies (APC −1·97%; 95% CI −2·21 to −1·73) but surged for solid tumours (APC 2·25%; 95% CI 2·10–2·39). Population ageing accounted for 77·1% of the post-inflection increase; COVID-19 contributions were transient.Interpretation: A structural acceleration in sepsis-associated cancer mortality began in the early 2010s, driven largely by solid tumours and exceeding demographic expectations. This identifies sepsis as a critical, structural determinant of cancer outcomes, necessitating prioritisation within oncologic survivorship guidelines and health system infrastructure.
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag097
Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey
Background: Primary central nervous system (CNS) tumors are rare malignancies with limited treatment options, resulting in high mortality. Unlike other solid tumors, CNS tumors present unique challenges that impact the health-related quality of life (HRQoL) of patients and caregivers. Effective management requires balancing oncologic treatment with the control of neurocognitive deficits, epilepsy, and other neurological symptoms. Methods: The European Society for Medical Oncology (ESMO) CNS Faculty conducted a consensus process to identify the most pressing educational priorities for physicians managing CNS malignancies. This process involved structured data collection and expert input to determine critical areas for disease-specific education and training. Results: The consensus process highlighted key educational gaps in managing CNS tumors, emphasizing the need for a multidisciplinary approach to optimize therapeutic strategies, improve survival outcomes, enhance HRQoL during treatment and survivorship, and facilitate access to emerging therapies. Physicians reported that comprehensive, disease-specific education is essential to address these challenges effectively. Conclusion: CNS tumors require targeted educational initiatives to equip healthcare providers with the knowledge and skills necessary for optimal patient care. The ESMO CNS Faculty consensus underscores the importance of structured, disease-specific training to improve outcomes, support HRQoL, and advance oncology education in the management of CNS malignancies.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag097
Open AccessEducational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey
Background: Primary central nervous system (CNS) tumors are rare malignancies with limited treatment options, resulting in high mortality. Unlike other solid tumors, CNS tumors present unique challenges that impact the health-related quality of life (HRQoL) of patients and caregivers. Effective management requires balancing oncologic treatment with the control of neurocognitive deficits, epilepsy, and other neurological symptoms. Methods: The European Society for Medical Oncology (ESMO) CNS Faculty conducted a consensus process to identify the most pressing educational priorities for physicians managing CNS malignancies. This process involved structured data collection and expert input to determine critical areas for disease-specific education and training. Results: The consensus process highlighted key educational gaps in managing CNS tumors, emphasizing the need for a multidisciplinary approach to optimize therapeutic strategies, improve survival outcomes, enhance HRQoL during treatment and survivorship, and facilitate access to emerging therapies. Physicians reported that comprehensive, disease-specific education is essential to address these challenges effectively. Conclusion: CNS tumors require targeted educational initiatives to equip healthcare providers with the knowledge and skills necessary for optimal patient care. The ESMO CNS Faculty consensus underscores the importance of structured, disease-specific training to improve outcomes, support HRQoL, and advance oncology education in the management of CNS malignancies.
- Open Access
- 6 January 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study
Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical practice remains variable. We conducted a multicenter retrospective study across seven Spanish hospitals to evaluate the clinical utility of NGS in glioma management, focusing on its impact on diagnosis and treatment selection based on the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). A total of 541 glioma patients diagnosed between 2018 and 2022 were included; 76% had glioblastomas and 24% other glioma subtypes. Among glioblastoma patients, 9% harbored ESCAT tier 1/2 alterations and 74% tier 3/4. Molecularly matched therapy was administered in 10.2% of glioblastoma cases. Objective responses were observed in 17.6% of glioblastoma and 33% of non-glioblastoma patients with ESCAT tier 1/2 alterations. Patients with tier 1/2 alterations experienced significantly longer progression-free survival compared to those with tier 3/4. These findings support genomic profiling of gliomas in research centers to expand therapeutic options in molecularly guided clinical trials.
- 6 January 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessClinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study
Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical practice remains variable. We conducted a multicenter retrospective study across seven Spanish hospitals to evaluate the clinical utility of NGS in glioma management, focusing on its impact on diagnosis and treatment selection based on the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). A total of 541 glioma patients diagnosed between 2018 and 2022 were included; 76% had glioblastomas and 24% other glioma subtypes. Among glioblastoma patients, 9% harbored ESCAT tier 1/2 alterations and 74% tier 3/4. Molecularly matched therapy was administered in 10.2% of glioblastoma cases. Objective responses were observed in 17.6% of glioblastoma and 33% of non-glioblastoma patients with ESCAT tier 1/2 alterations. Patients with tier 1/2 alterations experienced significantly longer progression-free survival compared to those with tier 3/4. These findings support genomic profiling of gliomas in research centers to expand therapeutic options in molecularly guided clinical trials.
- Open Access
- 21 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012143
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response
Background: The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response. Methods: Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1–3 weeks), and intermediate (6–8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests. Results: Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1–3 weeks of treatment. Conclusions: This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics.
- 21 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012143
Open AccessIntegrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response
Background: The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response. Methods: Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1–3 weeks), and intermediate (6–8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests. Results: Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1–3 weeks of treatment. Conclusions: This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics.
- Open Access
- 16 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (2) , 333-349
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Purpose: Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall survival in a cohort of patients with advanced cancer treated with immunotherapies. Experimental Design: In order to characterize the potential role of ultrasensitive ctDNA detection in the management of these patients, we have performed tumor whole-genome sequencing–informed, ultrasensitive ctDNA analysis—tracking approximately 1,800 tumor-specific mutations per patient—in a retrospective cohort (n = 136) and a prospective validation cohort (n = 66) across 24 cancer types treated with immune checkpoint inhibitors alone or in combination with bispecific antibodies or immune cell engagers. Results: Analyzing 1,455 longitudinal samples, we found that ctDNA molecular response measured as early as 3 weeks after treatment initiation correlated with improved progression-free and overall survival, whereas ctDNA clearance at any time strongly correlated with radiologic response and prolonged survival. Additionally, ctDNA dynamics distinguished true progression from pseudoprogression and predicted outcomes in patients receiving continued immunotherapy beyond initial progression. Conclusions: This study highlights the broader applicability of ultrasensitive ctDNA as a biomarker across cancer types and immunotherapy modalities.
- 16 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (2) , 333-349
Open AccessBroad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Purpose: Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall survival in a cohort of patients with advanced cancer treated with immunotherapies. Experimental Design: In order to characterize the potential role of ultrasensitive ctDNA detection in the management of these patients, we have performed tumor whole-genome sequencing–informed, ultrasensitive ctDNA analysis—tracking approximately 1,800 tumor-specific mutations per patient—in a retrospective cohort (n = 136) and a prospective validation cohort (n = 66) across 24 cancer types treated with immune checkpoint inhibitors alone or in combination with bispecific antibodies or immune cell engagers. Results: Analyzing 1,455 longitudinal samples, we found that ctDNA molecular response measured as early as 3 weeks after treatment initiation correlated with improved progression-free and overall survival, whereas ctDNA clearance at any time strongly correlated with radiologic response and prolonged survival. Additionally, ctDNA dynamics distinguished true progression from pseudoprogression and predicted outcomes in patients receiving continued immunotherapy beyond initial progression. Conclusions: This study highlights the broader applicability of ultrasensitive ctDNA as a biomarker across cancer types and immunotherapy modalities.
- Open Access
- 28 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e013072
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Background: Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progression/recurrence-free survival 2 (PRFS2) and progression-free survival 2 (PFS2) capture the time from randomization to objective recurrence/progression or death on the first subsequent therapy, potentially offering a more accurate measure of durable benefit than first-event endpoints. Our aim is to review the magnitude of this benefit and evaluate long-term endpoints as surrogates for overall survival (OS) in immunotherapy for solid malignancies. Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis searched Web of Science, National Institutes of Health Clinical Trials Registry, American Society of Clinical Oncology and European Society of Medical Oncology conference databases from inception until June 12, 2025, for anti-PD-(L)1-based randomized controlled phase II/III clinical trials (RCTs) in patients with solid malignancies that reported EFS2, PRFS2 or PFS2. HRs comparing ICI and non-ICI arms were pooled using a random-effects meta-analytic approach. Sensitivity analyses and meta-regressions assessed effect modifiers. A linear regression compared EFS2/PRFS2/PFS2 and EFS/disease-free survival (DFS)/PFS versus OS HRs. Results: 47 RCTs met inclusion criteria from 2,078 citations, comprising 58 intervention comparisons (ICs) and 34,973 patients. Non-small cell lung cancer (NSCLC) was the most investigated tumor (17 RCTs). Anti-PD-(L)1s performed generally worse when administered as a subsequent therapy in non-ICI-experienced patients (p<0.05). Early anti-PD-(L)1 use was associated with significantly improved EFS2/PRFS2/PFS2 (HR 0.72; 95% CI 0.68 to 0.76), with consistent findings across curative and recurrent/metastatic settings, and particularly strong effects in RCTs involving patients with deficient mismatch repair or high microsatellite instability tumors and those with more radiological responses. In 54 ICs reporting both OS and EFS2/PRFS2/PFS2 HRs, a strong correlation (R²=0.74) was observed across all RCTs, and an even stronger 0.86 specifically among patients with NSCLC (22 ICs). Conversely, EFS/DFS/PFS presented R² 0.39 across all RCTs (51 ICs), and 0.65 in NSCLC (21 ICs; p<0.01). Conclusions: Early use of anti-PD-(L)1 therapy is associated with prolonged disease control and may be linked to enhanced responsiveness to subsequent therapies, mostly based on NSCLC data. Additionally, EFS2/PRFS2/PFS2 are solid candidate surrogates for OS and could be considered for routine inclusion and prespecified into immunotherapy RCTs to better capture long-term benefit and inform regulatory, clinical, and reimbursement decision-making. PROSPERO registration number: CRD42024585378.
- 28 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e013072
Open AccessSecond-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Background: Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progression/recurrence-free survival 2 (PRFS2) and progression-free survival 2 (PFS2) capture the time from randomization to objective recurrence/progression or death on the first subsequent therapy, potentially offering a more accurate measure of durable benefit than first-event endpoints. Our aim is to review the magnitude of this benefit and evaluate long-term endpoints as surrogates for overall survival (OS) in immunotherapy for solid malignancies. Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis searched Web of Science, National Institutes of Health Clinical Trials Registry, American Society of Clinical Oncology and European Society of Medical Oncology conference databases from inception until June 12, 2025, for anti-PD-(L)1-based randomized controlled phase II/III clinical trials (RCTs) in patients with solid malignancies that reported EFS2, PRFS2 or PFS2. HRs comparing ICI and non-ICI arms were pooled using a random-effects meta-analytic approach. Sensitivity analyses and meta-regressions assessed effect modifiers. A linear regression compared EFS2/PRFS2/PFS2 and EFS/disease-free survival (DFS)/PFS versus OS HRs. Results: 47 RCTs met inclusion criteria from 2,078 citations, comprising 58 intervention comparisons (ICs) and 34,973 patients. Non-small cell lung cancer (NSCLC) was the most investigated tumor (17 RCTs). Anti-PD-(L)1s performed generally worse when administered as a subsequent therapy in non-ICI-experienced patients (p<0.05). Early anti-PD-(L)1 use was associated with significantly improved EFS2/PRFS2/PFS2 (HR 0.72; 95% CI 0.68 to 0.76), with consistent findings across curative and recurrent/metastatic settings, and particularly strong effects in RCTs involving patients with deficient mismatch repair or high microsatellite instability tumors and those with more radiological responses. In 54 ICs reporting both OS and EFS2/PRFS2/PFS2 HRs, a strong correlation (R²=0.74) was observed across all RCTs, and an even stronger 0.86 specifically among patients with NSCLC (22 ICs). Conversely, EFS/DFS/PFS presented R² 0.39 across all RCTs (51 ICs), and 0.65 in NSCLC (21 ICs; p<0.01). Conclusions: Early use of anti-PD-(L)1 therapy is associated with prolonged disease control and may be linked to enhanced responsiveness to subsequent therapies, mostly based on NSCLC data. Additionally, EFS2/PRFS2/PFS2 are solid candidate surrogates for OS and could be considered for routine inclusion and prespecified into immunotherapy RCTs to better capture long-term benefit and inform regulatory, clinical, and reimbursement decision-making. PROSPERO registration number: CRD42024585378.